{"id":"W2967398918","doi":"10.1016/s1470-2045(19)30407-3","title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":365,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; Bristol-Myers Squibb; Ono Pharmaceutical; European Society for Medical Oncology; Cancer Research Society; American Association for Cancer Research","keywords":"Nivolumab; Medicine; Docetaxel; Lung cancer; Internal medicine; Oncology; Clinical trial; Survival analysis; Cancer; Progressive disease; Chemotherapy; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01116992741928595,"score_gpt":0.26970985525713,"score_spread":0.258539927837844,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}